Spots Global Cancer Trial Database for solid cancers
Every month we try and update this database with for solid cancers cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors | NCT01106599 | Solid Cancers | GDC-0623 | 18 Years - | Genentech, Inc. | |
| A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors | NCT02323191 | Solid Cancers | Atezolizumab Emactuzumab | 18 Years - | Hoffmann-La Roche | |
| Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies | NCT02485119 | Neoplasms | BAY94-9343 | 20 Years - | Bayer | |
| A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors | NCT01068977 | Solid Cancers | bevacizumab MetMAb MetMAb | 18 Years - | Genentech, Inc. | |
| A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer | NCT00927589 | Solid Cancers | carboplatin docetaxel trastuzumab | 18 Years - | Genentech, Inc. | |
| A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors | NCT00747734 | Solid Cancers | MNRP1685A | 18 Years - | Genentech, Inc. | |
| A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors | NCT00909740 | Solid Cancers | MEGF0444A | 18 Years - | Genentech, Inc. | |
| A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies | NCT00977067 | Solid Cancers | GDC-0152 | 18 Years - | Genentech, Inc. | |
| A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma | NCT01226277 | Solid Cancers | GDC-0917 | 18 Years - | Genentech, Inc. | |
| A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors | NCT01075464 | Solid Cancers | MEGF0444A bevacizumab paclitaxel | 18 Years - | Genentech, Inc. | |
| A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors | NCT02323191 | Solid Cancers | Atezolizumab Emactuzumab | 18 Years - | Hoffmann-La Roche | |
| A Study of the Safety and Pharmacokinetics of GDC-0152, Administered Intravenously to Patients With Locally Advanced or Metastatic Malignancies | NCT00977067 | Solid Cancers | GDC-0152 | 18 Years - | Genentech, Inc. | |
| A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors | NCT00907205 | Advanced or Met... Cancer Solid Cancers | SF1126 | 18 Years - | Semafore Pharmaceuticals | |
| 68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor: a Pragmatic Study | NCT05228106 | Solid Cancers | [68Ga]-PSMA-617 | - | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | |
| A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma | NCT01359696 | Solid Tumor | GDC-0425 gemcitabine | 18 Years - | Genentech, Inc. | |
| GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors | NCT01332604 | Solid Cancers | GDC-0980 bevacizumab capecitabine mFOLFOX6 | 18 Years - | Genentech, Inc. | |
| A Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors | NCT01090960 | Solid Cancers | GDC-0068 | 18 Years - | Genentech, Inc. | |
| A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors | NCT00954642 | Solid Cancers | bevacizumab MNRP1685A paclitaxel | 18 Years - | Genentech, Inc. | |
| Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer | NCT01820299 | Solid Cancers | Grape Seed Extr... Vitamin D | 18 Years - | Medical University of South Carolina | |
| A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors | NCT01139723 | Solid Cancers | MINT1526A bevacizumab | 18 Years - | Genentech, Inc. | |
| A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer | NCT00927589 | Solid Cancers | carboplatin docetaxel trastuzumab | 18 Years - | Genentech, Inc. | |
| A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers | NCT02367196 | Hematologic Neo... | CC-90002 Rituximab | 18 Years - | Celgene | |
| Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer | NCT01820299 | Solid Cancers | Grape Seed Extr... Vitamin D | 18 Years - | Medical University of South Carolina | |
| A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable | NCT00876109 | Solid Cancers | GDC-0941 | 18 Years - | Genentech, Inc. | |
| A Study of the Safety and Pharmacokinetics of MEGF0444A Administered to Patients With Advanced Solid Tumors | NCT00909740 | Solid Cancers | MEGF0444A | 18 Years - | Genentech, Inc. | |
| Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma | NCT01356173 | Non-Hodgkin's L... | GDC-0349 | 18 Years - | Genentech, Inc. | |
| A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors | NCT02174172 | Solid Cancers | Atezolizumab Bevacizumab Interferon alfa... Ipilimumab Obinutuzumab PEG-interferon ... | 18 Years - | Hoffmann-La Roche | |
| A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors | NCT02174172 | Solid Cancers | Atezolizumab Bevacizumab Interferon alfa... Ipilimumab Obinutuzumab PEG-interferon ... | 18 Years - | Hoffmann-La Roche | |
| A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors | NCT01068977 | Solid Cancers | bevacizumab MetMAb MetMAb | 18 Years - | Genentech, Inc. | |
| A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma | NCT01359696 | Solid Tumor | GDC-0425 gemcitabine | 18 Years - | Genentech, Inc. | |
| A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors | NCT02317419 | Cancer | RO6927005 RO6927005 gemcitabine nab-paclitaxel | 18 Years - | Hoffmann-La Roche | |
| A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers | NCT02367196 | Hematologic Neo... | CC-90002 Rituximab | 18 Years - | Celgene | |
| GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors | NCT01332604 | Solid Cancers | GDC-0980 bevacizumab capecitabine mFOLFOX6 | 18 Years - | Genentech, Inc. | |
| GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors | NCT01332604 | Solid Cancers | GDC-0980 bevacizumab capecitabine mFOLFOX6 | 18 Years - | Genentech, Inc. | |
| 68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor: a Pragmatic Study | NCT05228106 | Solid Cancers | [68Ga]-PSMA-617 | - | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | |
| A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors | NCT02174172 | Solid Cancers | Atezolizumab Bevacizumab Interferon alfa... Ipilimumab Obinutuzumab PEG-interferon ... | 18 Years - | Hoffmann-La Roche | |
| Clinical and Therapeutic Impact of Large Genomic Studies at Diagnosis in Pediatric Solid Cancers | NCT06171971 | Pediatric Solid... | 1 Year - 22 Years | University Hospital, Strasbourg, France | ||
| A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study | NCT00096941 | Solid Cancers | Pertuzumab | - | Genentech, Inc. | |
| GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors | NCT01332604 | Solid Cancers | GDC-0980 bevacizumab capecitabine mFOLFOX6 | 18 Years - | Genentech, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
